



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Ziva MESSIKA et al

Application No.: 09/445,185

Filed: March 7, 2000

For: PREPARATION OF GLYCOSYLATED TUMOR NECROSIS FACTOR

Art Unit: 1647

Examiner: J. Seharaseyon

Washington, D.C.

Atty.'s Docket: MESSIKA=1

Date: July 11, 2001

TECH CENTER 1600/2900

JUL 13 2001

RECEIVED

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a ☒ Amendment ☐ _____
in the above-identified application.☐ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.☒ No additional fee is required.☐ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20	0
INDEP.	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 40	\$
+ 135	\$
ADDITIONAL FEE TOTAL	
\$	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 80	\$
+ 270	\$
TOTAL	
\$	

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

☐ First - \$ 55.00
☐ Second - \$ 195.00
☐ Third - \$ 445.00
☐ Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

☐ First - \$ 110.00
☐ Second - \$ 390.00
☐ Third - \$ 890.00
☐ Fourth - \$ 1390.00

Month After Time Period Set

☐ Less fees (\$ _____) already paid for ____ month(s) extension of time on _____.☐ Please charge my Deposit Account No. 02-4035 in the amount of \$ _____.☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ _____.☐ A check in the amount of \$ _____ is attached (check no.).☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Roger L. Browdy
Registration No. 25,618Facsimile: (202) 737-3528
Telephone: (202) 628-5197



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: MESSIKA=1

In re Application of:)	Art Unit: 1647
)	
Ziva MESSIKA et al)	Examiner: J. Seharaseyon
)	
Appln. No.: 09/445,105)	Washington, D.C.
)	
Filed: March 7, 2000)	July 11, 2001
)	
For: PREPARATION OF)	
GLYCOSYLATED TUMOR)	
NECROSIS FACTOR)	

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of June 19, 2001,
please amend as follows:

IN THE CLAIMS

Rev B2

2. A method for preparing isolated biologically
active glycosylated human tumor necrosis factor, comprising

(a) ligating DNA encoding human TNF or a
physiologically active variant thereof to a replicable
expression vehicle to obtain a replicable recombinant DNA
comprising said DNA and said replicable expression vehicle;

(b) transforming eukaryotic cells with said
replicable recombinant DNA to form transformants;

61

#6/ electron
amdt 2
JUL 13 2001
TECH CENTER 1600/2900
RECEIVED